On October 23, 2025 Nantes-based biotech company XENOTHERA is accelerating its developments in oncology with several multispecific glyco humanized antibody (GH-pAb) programs, reported new clinical milestones and major publications in international journals and conferences.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Clinical advances for XON7 in solid tumors
The XON7 program is developing a GH-pAb antibody targeting a unique combination of tumor antigens expressed in several solid cancers. The clinical trial, conducted in France and Belgium since late 2023 (FIPO trial, NCT06154291), is supported by BPI France.
In September 2025, the scientific committee approved the start of a backfilling phase at a dose of 16 mg, based on pharmacokinetic data obtained from patients.
The most recent results will be presented at the ESMO (Free ESMO Whitepaper) 2025 congress in Berlin (poster 984B, October 19, 12:00 p.m.–12:45 p.m.).
LIS22: positive signals in peripheral T-cell lymphomas
The LIS22 program, dedicated to peripheral T-cell lymphoma (PTCL) – a serious disease with high unmet medical need – has been in clinic in France and Italy since mid-2024 (PALT trial, NCT06495723), with funding from France 2030 i-DEMO program.
The scientific advisory board has recently approved the move to a 7.5 mg dose, highlighting the candidate’s lack of toxicity and therapeutic potential.
LIS22 was the subject of an oral presentation and an abstract published in the proceedings of the ICML 2025 world congress in Lugano (International Conference on Malignant Lymphoma).
International publication for XON9 in hepatocellular carcinoma
The XON9 program explores the therapeutic potential of a new GH-pAb antibody targeting hepatocellular carcinoma.
The results have just been published in the special edition on hepatology of the International Journal of Molecular Sciences (IJMS).
The article, entitled "XON9 – A Glyco-Humanized Polyclonal Antibody Effective Against Hepatocellular Carcinoma" (Royer et al.), describes the in vitro and in vivo data and demonstrates the superiority of XON9 over Sorafenib, the current standard of care for this cancer.
These results reinforce XENOTHERA’s strategy of developing a new generation of multispecific antibodies to address unmet needs in oncology.
"We are delighted to be advancing science for the benefit of patients and confirming the value of our first-in-class technology in serious cancers. The multispecific and multimodal approach represents a tremendous innovation, and we believe that the future will confirm its value for patients. These results already confirm XENOTHERA’s credibility in the field of oncology. I would like to congratulate our teams on these magnificent advances and thank the patients and investigators for their commitment to these trials." — Dr. Odile Duvaux, President of XENOTHERA
(Press release, Xenothera, OCT 23, 2025, View Source [SID1234656953])